An optimal PSA response, defined as ≤0.2 ng/mL, is achieved by approximately 51% of mHSPC patients 6–8 months after treatment with androgen deprivation therapy (ADT) and androgen receptor pathway ...

There are different ways to manage fatigue during prostate cancer treatment, including exercise, sleep, complementary ...

Dr. Ali Kasraeian from Kasraeian Urology is the first in our area to utilize a new minimally invasive treatment, called Focal Therapy, that precisely targets and destroys prostate cancer tumors.

New AI tool from UC San Diego and collaborators precisely maps the urethra on MRI to make prostate cancer radiation safer and reduce urinary side effects. Running on SDSC’s Expanse supercomputer, the ...

Prostate Cancer Survivor, Jerry McCormick, urges Black men 45 years and older to get screened as soon as possible, because early detection could save their life.

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS ...

Phase 3 PEACE-2 data indicates that the addition of cabazitaxel to ADT plus RT did not improve clinical PFS in very high risk ...

BALTIMORE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Today, the American Urological Association (AUA), in partnership with the Society of Urologic Oncology (SUO), released the 2026 amendment to the Early ...

Performed in a single session without any surgical incisions or scarring, the treatment utilizes an advanced fusion-guided ...

In the real-world, Pluvicto showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal-world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead ...

In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPCReal‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead ...